Morphologic and quantitative assessment of CD20+ B cell infiltrates in rheumatoid arthritis-associated nonspecific interstitial pneumonia and usual interstitial pneumonia

Arthritis and Rheumatism

Volumn 54, Issue 2, 2006, Pages 635-641

  Atkins, Sarah R ^a   Turesson, Carl ^a   Myers, Jeffery L ^a   Tazelaar, Henry D ^a   Ryu, Jay H ^a   Matteson, Eric L ^a   Bongartz, Tim ^a,b  

^a Mayo Clinic   (United States)

^b MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD20 ANTIBODY;

ADULT; AGED; ARTICLE; B LYMPHOCYTE; CELL HYPERPLASIA; CELL STRUCTURE; CLINICAL ARTICLE; COMPUTER ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HISTOLOGY; HUMAN; HUMAN TISSUE; IDIOPATHIC DISEASE; IMAGE ANALYSIS; INTERSTITIAL PNEUMONIA; JOINT DESTRUCTION; LUNG INFILTRATE; LYMPHOCYTIC INFILTRATION; MALE; OPEN LUNG BIOPSY; PATHOGENESIS; PLASMA CELL; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RHEUMATOID ARTHRITIS; SMOKING; UNITED STATES;

ADULT; AGED; ANTIGENS, CD20; ARTHRITIS, RHEUMATOID; B-LYMPHOCYTES; BIOLOGICAL MARKERS; BIOPSY; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG; LUNG DISEASES, INTERSTITIAL; MALE; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; PLASMA CELLS; PROTEOGLYCANS; RESPIRATORY FUNCTION TESTS; SYNDECAN-1; SYNDECANS;

EID: 32444431507     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.21758     Document Type: Article

References (28)

1. Turesson C, Jacobsson L, Bergstrom U. Extra-articular rheumatoid arthritis: prevalence and mortality. Rheumatology (Oxford) 1999;38:668-74.
2. Turesson C, O'Fallon WM, Crowson CS, Gabriel SE, Matteson EL. Occurrence of extraarticular disease manifestations is associated with excess mortality in a community based cohort of patients with rheumatoid arthritis. J Rheumatol 2002;29:62-7.
3. American Thoracic Society and the European Respiratory Society. Idiopathic pulmonary fibrosis: diagnosis and treatment: international consensus statement [review]. Am J Respir Crit Care Med 2000;161:646-64.
4. Katzenstein AL, Myers JL. Idiopathic pulmonary fibrosis: clinical relevance of pathologic classification [review]. Am J Respir Crit Care Med 1998;157:1301-15.
5. Travis WD, Matsui K, Moss J, Ferrans VJ. Idiopathic nonspecific interstitial pneumonia: prognostic significance of cellular and fibrosing patterns: survival comparison with usual interstitial pneumonia and desquamative interstitial pneumonia. Am J Surg Pathol 2000;24:19-33.
6. Nicholson AG, Colby TV, du Bois RM, Hansell DM, Wells AU. The prognostic significance of the histologic pattern of interstitial pneumonia in patients presenting with the clinical entity of cryptogenic fibrosing alveolitis. Am J Respir Crit Care Med 2000;162:2213-7.
7. Daniil ZD, Gilchrist FC, Nicholson AG, Hansell DM, Harris J, Colby TV, et al. A histologic pattern of nonspecific interstitial pneumonia is associated with a better prognosis than usual interstitial pneumonia in patients with cryptogenic fibrosing alveolitis. Am J Respir Crit Care Med 1999;160:899-905.
8. Bjoraker JA, Ryu JH, Edwin MK, Myers JL, Tazelaar HD, Schroeder DR, et al. Prognostic significance of histopathologic subsets in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 1998;157:199-203.
9. Mason RJ, Schwarz MI, Hunninghake GW, Musson RA. NHLBI workshop summary: pharmacological therapy for idiopathic pulmonary fibrosis: past, present, and future [review]. Am J Respir Crit Care Med 1999;160:1771-7.
10. Turesson C, Matteson EL, Colby TV, Vuk-Pavlovic Z, Vassallo R, Weyand CM, et al. Increased CD4+ T cell infiltrates in rheumatoid arthritis-associated interstitial pneumonitis compared with idiopathic interstitial pneumonitis. Arthritis Rheum 2005;52:73-9.
11. Nakamura Y, Chida K, Suda T, Hayakawa H, Iwata M, Imokawa S, et al. Nonspecific interstitial pneumonia in collagen vascular diseases: comparison of the clinical characteristics and prognostic significance with usual interstitial pneumonia. Sarcoidosis Vasc Diffuse Lung Dis 2003;20:235-41.
12. Campbell DA, Poulter LW, Janossy G, du Bois RM. Immunohistological analysis of lung tissue from patients with cryptogenic fibrosing alveolitis suggesting local expression of immune hypersensitivity. Thorax 1985;40:405-11.
13. Wallace WA, Howie SE, Krajewski AS, Lamb D. The immunological architecture of B-lymphocyte aggregates in cryptogenic fibrosing alveolitis. J Pathol 1996;178:323-9.
14. Chapman JR, Charles PJ, Venables PJ, Thompson PJ, Haslam PL, Maini RN, et al. Definition and clinical relevance of antibodies to nuclear ribonucleoprotein and other nuclear antigens in patients with cryptogenic fibrosing alveolitis. Am Rev Respir Dis 1984;130:439-43.
15. Wallace WA, Roberts SN, Caldwell H, Thornton E, Greening AP, Lamb D, et al. Circulating antibodies to lung protein(s) in patients with cryptogenic fibrosing alveolitis. Thorax 1994;49:218-24.
16. Lindenau S, Scholze S, Odendahl M, Dorner T, Radbruch A, Burmester GR, et al. Aberrant activation of B cells in patients with rheumatoid arthritis [review]. Ann N Y Acad Sci 2003;987:246-8.
17. Schroder AE, Greiner A, Seyfert C, Berek C. Differentiation of B cells in the nonlymphoid tissue of the synovial membrane of patients with rheumatoid arthritis. Proc Natl Acad Sci U S A 1996;93:221-5.
18. Shiokawa S, Matsumato N, Nishimura J. Clonal analysis of B cells in the synovial membrane of patients with rheumatoid arthritis. Scand J Rheumatol 2003;32:12-8.
19. Reparon-Schuijt CC, van Esch WJ, van Kooten C, Schellekens GA, de Jong BA, van Venrooij WJ, et al. Secretion of anti-citrulline-containing peptide antibody by B lymphocytes in rheumatoid arthritis. Arthritis Rheum 2001;44:41-7.
20. Zeng X, Ai M, Tian X, Gan X, Shi Y, Song Q, et al. Diagnostic value of anti-cyclic citrullinated peptide antibody in patients with rheumatoid arthritis. J Rheumatol 2003;30:1451-5.
21. Leandro MJ, Edwards JC, Cambridge G. Clinical outcome in 22 patients with rheumatoid arthritis treated with B lymphocyte depletion. Ann Rheum Dis 2002;61:883-8.
22. Edwards JC, Szczepanski L, Szechinski J, Filipowicz-Sosnowska A, Emery P, Close DR, et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 2004;350:2572-81.
23. Sanderson RD, Lalor P, Bernfield M. B lymphocytes express and lose syndecan at specific stages of differentiation. Cell Regul 1989;1:27-35.
24. Bohm BB, Aigner T, Blobel CP, Kalden JR, Burkhardt H. Highly enhanced expression of the disintegrin metalloproteinase MDC15 (metargidin) in rheumatoid synovial tissue. Arthritis Rheum 2001;44:2046-54.
25. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
26. Toyoshima E, Ohsaki Y, Nishigaki Y, Fujimoto Y, Kohgo Y, Kikuchi K. Expression of syndecan-1 is common in human lung cancers independent of expression of epidermal growth factor receptor. Lung-Cancer 2001;31:193-202.
27. King TE Jr, Safrin S, Starko KM, Brown KK, Noble PW, Raghu G, et al. Analyses of efficacy end points in a controlled trial of interferon-γlb for idiopathic pulmonary fibrosis. Chest 2005;127:171-7.
28. Moyron-Quiroz JE, Rangel-Moreno J, Kusser K, Hartson L, Sprague F, Goodrich S, et al. Role of inducible bronchus associated lymphoid tissue (iBALT) in respiratory immunity. Nat Med 2004;10:927-34.